These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35524875)

  • 1. Intensive management of obesity in people with Prader-Willi syndrome.
    Nolan BJ; Proietto J; Sumithran P
    Endocrine; 2022 Jun; 77(1):57-62. PubMed ID: 35524875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination phentermine and topiramate for weight maintenance: the first Australian experience.
    Neoh SL; Sumithran P; Haywood CJ; Houlihan CA; Lee FT; Proietto J
    Med J Aust; 2014 Aug; 201(4):224-6. PubMed ID: 25164851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search.
    Goldman VE; Naguib MN; Vidmar AP
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
    Diene G; Angulo M; Hale PM; Jepsen CH; Hofman PL; Hokken-Koelega A; Ramesh C; Turan S; Tauber M
    J Clin Endocrinol Metab; 2022 Dec; 108(1):4-12. PubMed ID: 36181471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
    Song JE; Ko HJ; Kim AS
    Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.
    Sani E; Prato GD; Zenti MG; Bordugo A; Trombetta M; Bonora E
    Endocr Metab Immune Disord Drug Targets; 2022; 22(10):1053-1057. PubMed ID: 35538810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi Syndrome and type 2 diabetes.
    Giménez-Palop O; Romero A; Casamitjana L; Pareja R; Rigla M; Caixàs A
    Endocrinol Diabetes Nutr (Engl Ed); 2024 Feb; 71(2):83-87. PubMed ID: 38553173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
    Consoli A; Çabal Berthoumieu S; Raffin M; Thuilleaux D; Poitou C; Coupaye M; Pinto G; Lebbah S; Zahr N; Tauber M; Cohen D; Bonnot O
    Transl Psychiatry; 2019 Nov; 9(1):274. PubMed ID: 31685813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.
    Ng NBH; Low YW; Rajgor DD; Low JM; Lim YY; Loke KY; Lee YS
    Clin Endocrinol (Oxf); 2022 Feb; 96(2):144-154. PubMed ID: 34448208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prader-Willi Syndrome: Possibilities of Weight Gain Prevention and Treatment.
    Erhardt É; Molnár D
    Nutrients; 2022 May; 14(9):. PubMed ID: 35565916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature.
    Bonnot O; Cohen D; Thuilleaux D; Consoli A; Cabal S; Tauber M
    Eur J Pediatr; 2016 Jan; 175(1):9-18. PubMed ID: 26584571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight Loss Pharmacotherapy: Current and Future Therapies.
    Jordan G; Young S; Alemán JO
    Gastrointest Endosc Clin N Am; 2024 Oct; 34(4):591-608. PubMed ID: 39277293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Obesity treatment with liraglutide in a patient with Prader-Willi syndrome: a case report].
    Cadena-Obando DA; Molina-Ayala MA; Ferreira-Hermosillo A
    Nutr Hosp; 2018 May; 35(3):743-746. PubMed ID: 29974787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-center real-life experience with testosterone treatment in adult men with Prader-Willi syndrome.
    Nolan BJ; Proietto J; Sumithran P
    Am J Med Genet A; 2022 Sep; 188(9):2637-2641. PubMed ID: 35532976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.
    Lim F; Bellows BK; Tan SX; Aziz Z; Woo Baidal JA; Kelly AS; Hur C
    JAMA Netw Open; 2023 Aug; 6(8):e2329178. PubMed ID: 37651143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
    Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
    Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topiramate effectiveness in Prader-Willi syndrome.
    Smathers SA; Wilson JG; Nigro MA
    Pediatr Neurol; 2003 Feb; 28(2):130-3. PubMed ID: 12699864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.
    Grunvald E; Shah R; Hernaez R; Chandar AK; Pickett-Blakely O; Teigen LM; Harindhanavudhi T; Sultan S; Singh S; Davitkov P;
    Gastroenterology; 2022 Nov; 163(5):1198-1225. PubMed ID: 36273831
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.